Allspring Global Investments Holdings LLC Boosts Holdings in Prestige Consumer Healthcare Inc. (NYSE:PBH)

Allspring Global Investments Holdings LLC lifted its stake in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) by 3.1% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,624,501 shares of the company’s stock after buying an additional 49,331 shares during the quarter. Allspring Global Investments Holdings LLC’s holdings in Prestige Consumer Healthcare were worth $126,274,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently bought and sold shares of PBH. JPMorgan Chase & Co. grew its holdings in shares of Prestige Consumer Healthcare by 3.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 272,255 shares of the company’s stock worth $19,630,000 after acquiring an additional 8,533 shares during the period. Geode Capital Management LLC boosted its position in shares of Prestige Consumer Healthcare by 4.0% during the third quarter. Geode Capital Management LLC now owns 1,326,794 shares of the company’s stock valued at $95,678,000 after purchasing an additional 50,961 shares in the last quarter. Sequoia Financial Advisors LLC grew its stake in Prestige Consumer Healthcare by 12.9% in the third quarter. Sequoia Financial Advisors LLC now owns 9,824 shares of the company’s stock worth $708,000 after purchasing an additional 1,120 shares during the period. Avior Wealth Management LLC raised its holdings in Prestige Consumer Healthcare by 1,570.7% in the fourth quarter. Avior Wealth Management LLC now owns 8,554 shares of the company’s stock worth $668,000 after purchasing an additional 8,042 shares in the last quarter. Finally, Barclays PLC lifted its position in Prestige Consumer Healthcare by 346.3% during the third quarter. Barclays PLC now owns 92,444 shares of the company’s stock valued at $6,665,000 after buying an additional 71,730 shares during the period. 99.95% of the stock is owned by institutional investors.

Insider Transactions at Prestige Consumer Healthcare

In related news, CEO Ronald M. Lombardi sold 10,875 shares of Prestige Consumer Healthcare stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $82.60, for a total transaction of $898,275.00. Following the transaction, the chief executive officer now directly owns 320,952 shares in the company, valued at approximately $26,510,635.20. The trade was a 3.28 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 1.60% of the stock is currently owned by company insiders.

Prestige Consumer Healthcare Stock Down 1.3 %

PBH stock opened at $86.03 on Wednesday. The stock has a market capitalization of $4.25 billion, a P/E ratio of 20.15, a P/E/G ratio of 2.43 and a beta of 0.50. The company has a debt-to-equity ratio of 0.56, a current ratio of 3.68 and a quick ratio of 2.10. Prestige Consumer Healthcare Inc. has a 1-year low of $62.35 and a 1-year high of $88.36. The business has a fifty day moving average price of $79.28 and a 200-day moving average price of $75.63.

Prestige Consumer Healthcare (NYSE:PBH) last issued its earnings results on Thursday, February 6th. The company reported $1.22 earnings per share for the quarter, topping analysts’ consensus estimates of $1.18 by $0.04. Prestige Consumer Healthcare had a return on equity of 12.36% and a net margin of 19.13%. Equities analysts forecast that Prestige Consumer Healthcare Inc. will post 4.5 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on PBH shares. Raymond James raised shares of Prestige Consumer Healthcare to a “moderate buy” rating in a research report on Thursday, December 19th. Sidoti cut shares of Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 price objective on the stock. in a report on Monday, December 9th. Canaccord Genuity Group lifted their target price on shares of Prestige Consumer Healthcare from $93.00 to $100.00 and gave the company a “buy” rating in a report on Friday, February 7th. StockNews.com upgraded Prestige Consumer Healthcare from a “hold” rating to a “buy” rating in a research note on Friday, January 24th. Finally, DA Davidson raised their price objective on Prestige Consumer Healthcare from $95.00 to $104.00 and gave the company a “buy” rating in a research report on Friday, February 7th. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $92.50.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.